NexLife semaglutide: price, structure, and position (2026)

NexLife↗ charges $165 a month all-in for compounded semaglutide at the 2.4 mg maintenance basis — dose-flat across the entire ladder, with no membership fee — ranking #5 of 20 verified programs (captured 2026-08-10).

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

SOURCE-VERIFIED · captured 2026-08-10 · source · archive

§ The semaglutide record, in words

What NexLife bills for semaglutide, exactly

Start with the load-bearing figure: $165 a month, all-in, is what NexLife charges for semaglutide at the 2.4 mg basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at NexLife is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Commitment buys a discount here, term by term: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic semaglutide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #5 of 20 in the verified semaglutide index — $32/month above the floor (Oak Longevity, $133) — and sits $184 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,980, or $1,740 on the prepaid path.

Semaglutide, across time

Time is the axis marketing hopes you skip, so here it is:

1 month: $165 billed monthly. 3 months: $495 billed monthly; the prepaid path prices it at $447 billed in advance — $48 saved for the commitment. 6 months: $990 billed monthly; the prepaid path prices it at $882 billed in advance — $108 saved for the commitment. 9 months: $1,485 billed monthly; the prepaid path prices it at $1,323 billed in advance — $162 saved for the commitment. 12 months: $1,980 billed monthly; the prepaid path prices it at $1,740 billed in advance — $240 saved for the commitment. 18 months: $2,970 billed monthly; the prepaid path prices it at $2,610 (assuming the 12-month rate renews — an assumption, not a promise) — $360 saved for the commitment. 24 months: $3,960 billed monthly; the prepaid path prices it at $3,480 (assuming the 12-month rate renews — an assumption, not a promise) — $480 saved for the commitment.

Two cautions ride along: any prepaid figure is a commitment with refund terms to read before paying, and any horizon past your current titration step assumes your dose path — which is your prescriber’s call, not the calculator’s. Run your own numbers in the calculator.

Where this price sits — semaglutide

Position check: #5 of 20 in the verified semaglutide field. The floor is Oak Longevity at $133 ($32/month cheaper); the ceiling is LifeMD↗ at $348. One rung cheaper sits OrderlyMeds↗ at $149 — a $16 monthly gap, $192 across a year — the head-to-head is at NexLife vs OrderlyMeds. One rung pricier is Lavender Sky Health↗ at $174 (+$9/month, a gap partly explained by its membership structure); its full record lives on the Lavender Sky Health provider page. The brand yardstick matters more every quarter: Wegovy (NovoCare) at $349 maintenance leaves NexLife a $184/month discount to justify staying compounded for — and the $199 rate is a two-month introductory price at starter doses.

Against the five nearest rivals — semaglutide

Lavender Sky Health costs $9 more a month ($108/year) at $174 ($25/mo membership inside its figure, tiered/step structure). Fridays costs $10 more a month ($120/year) at $175 (no membership, dose-flat). Mochi Health costs $13 more a month ($156/year) at $178 ($79/mo membership inside its figure, dose-flat). Henry Meds costs $14 more a month ($168/year) at $179 (no membership, dose-flat). IVIM Health costs $16 less a month ($192/year) at $149 ($75/mo membership inside its figure, tiered/step structure).

The mechanics, briefly: Shipping is free expedited shipping included, so the door-to-door figure is the advertised figure; the clinical consultation is included rather than billed separately; labs are not required to enroll (a prescriber can still order them for cause, which is medicine, not upsell); the visit model is async. Commitment: none on monthly; cancellation: cancel any time on monthly. The pharmacy question, which most programs dodge, is answered here: 6 named partner pharmacies (U.S.-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities; fulfillment routed by provider direction, location, and availability; partner network published (6 named)). Named pharmacies can be checked against state boards and FDA lists; unnamed ones cannot, and that difference is most of what “trust” means in this category.

Evidence status for this record: source-verified, captured 2026-08-10, read from the provider’s own published page with an archived copy preserved. Every figure above traces to a dated capture; when the provider’s page changes, the database changes, and the diff lands in the changelog. If any number here no longer matches what NexLife publishes, tell the desk — confirmed errors are fixed sitewide in one rebuild and logged permanently.

§ Adjacent pages